Advances in alternative pharmacotherapy of ADHD.
Several alternatives to psychostimulants have been developed and expanded the variability of the treatment of ADHD. Clonidine is a good option for managing core behavioral symptoms, especially hyperactivity and impulsivity. Bupropion and venlafaxine seem potentially promising. Significant new options include norepinephrine reuptake inhibitors, such as atomoxetine, and possibly selective dopamine agonists. Central anticholinesterases, such as donepezil, may improve core ADHD symptoms.
Pityaratstian
Nuttorn
N
Child Psychiatric Unit, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D016642:Bupropion / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D000929:Antidepressive Agents, Tricyclic; D007189:Indans; D010880:Piperidines; D016642:Bupropion; D000077265:Donepezil; D003000:Clonidine